Hebei Changshan expands reach with Turkmenistan drug approval, deputy GM resigns

Hebei Changshan Biochemical Pharmaceutical has successfully obtained a drug registration certificate for its heparin sodium injection in Turkmenistan, valid for five years. This approval is expected to positively impact the company's efforts to expand into overseas markets, although overseas sales of heparin preparations currently constitute a small proportion of its total operating revenue. The company cautions investors about potential risks from changes in overseas market policies, exchange rate fluctuations, and market competition.

In a separate announcement, Li Zhihua, the deputy general manager, submitted his resignation due to personal reasons, effective upon delivery of his report to the company's board. His original term was set from December 27, 2024, to December 26, 2027. Li will continue to hold other positions within the company, and his resignation as deputy general manager is not expected to affect daily production and operations.

As of the announcement, Li Zhihua holds 290,000 shares of the company. The management of these shares will adhere to relevant laws and regulations following his resignation. The company expressed gratitude for his contributions during his tenure as deputy general manager.